Mavorixafor Patent Expiration

Mavorixafor was first introduced by X4 Pharmaceuticals Inc in its drug Xolremdi on Apr 26, 2024.

Mavorixafor Patents

Given below is the list of patents protecting Mavorixafor, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Xolremdi	US10548889	Compositions of CXCR4 inhibitors and methods of preparation and use	Dec 11, 2038	X4 Pharms
Xolremdi	US11045461	Compositions of CXCR4 inhibitors and methods of preparation and use	Dec 11, 2038	X4 Pharms
Xolremdi	US10610527	Methods for treating immunodeficiency disease	Dec 22, 2036	X4 Pharms
Xolremdi	US11219621	Methods for treating immunodeficiency disease	Dec 22, 2036	X4 Pharms
Xolremdi	US10953003	Methods for treating cancer	Dec 14, 2036	X4 Pharms

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List